Patents Examined by Jagadishwar R. Samala
  • Patent number: 11116599
    Abstract: Imaging marker embodiments that may be used for marking sites within a patient's body are discussed. Some imaging marker embodiments are particularly useful for imaging with ultrasound imaging modalities and some imaging marker embodiments may be suitable for imaging with multiple modes of imaging modalities. Method embodiments for making and using imaging markers are also discussed herein.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: September 14, 2021
    Assignee: View Point Medical, Inc.
    Inventors: William Blair, Mike Jones, John Merritt
  • Patent number: 11116782
    Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 14, 2021
    Assignee: Celgene Corporation
    Inventor: Jerome B. Zeldis
  • Patent number: 11110184
    Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: September 7, 2021
    Assignee: Translatum Medicus Inc.
    Inventor: Shelley Romayne Boyd
  • Patent number: 11103602
    Abstract: A method for producing a solution including a positron emitting zinc cation of 63Zn, and the method comprises bombarding a solution target including 63Cu with high energy protons to produce a solution including a positron emitting zinc cation. A method for detecting or ruling out Alzheimer's disease in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to ?-amyloid in the patient, and acquiring an image to detect the presence or absence of ?-amyloid in the patient. A method for detecting or ruling out cancer in a patient comprises administering to a patient a detectable amount of a compound including a positron emitting zinc cation, wherein the zinc cation is targeted to tissue in the patient; and acquiring an image using a medical imaging technique to detect zinc distribution in tissue in the patient.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: August 31, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Timothy R. Degrado, Mukesh K. Pandey, Hendrik Petrus Engelbrecht, Val J. Lowe
  • Patent number: 11097018
    Abstract: Provided herein are compounds for the imaging and treatment of TDP43-mediated disorders. The compounds disclosed bind TDP43 aggregates and may be used to diagnose and treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: August 24, 2021
    Assignee: Washington University
    Inventors: Vijay Sharma, Jothilingam Sivapackiam, Sundaram S. M. Guruswami
  • Patent number: 11097017
    Abstract: In some aspects, the present disclosure provides novel ligands, which may be used to make novel MRI contrast agents for the detection of zinc. In further aspects, by the present disclosure also provides methods of using as imaging agents and compositions thereof.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: August 24, 2021
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Christian Preihs, Jing Yu, Veronica Clavijo Jordan, Yunkou Wu, Khaled Nasr, A. Dean Sherry, Sara Chirayil
  • Patent number: 11091449
    Abstract: Disclosed are: an intermediate capable of high-purity synthesis of gadobutrol which can be used as an MRI contrast agent; and a gadobutrol production method using same. The gadobutrol intermediate is represented by Chemical Formula 2 in the specification.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: August 17, 2021
    Assignee: ENZYCHEM LIFESCIENCES CORPORATION
    Inventors: Jae Young Lee, Jong Soo Lee, Byung Kyu Kang, Sang Oh Lee, Byouong Woo Lee, Dae Myoung Yun, Jae Hun Bang, Choi Kyung Seok
  • Patent number: 11083803
    Abstract: A sterile aqueous composition suitable for use as an MRI contrast agent includes 100 to 600 mM ascorbate; and 100-600 mM sodium, meglumine, or a combination thereof. The composition preferably has an osmolarity of 200 to 1400 mOsm/L.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: August 10, 2021
    Assignee: Duke University
    Inventor: Christopher David Lascola
  • Patent number: 11065201
    Abstract: The present invention relates to a composition comprising non-water soluble carbohydrates, wherein at least 50% of the non-water soluble carbohydrates are carbohydrates selected from derivatives of lactose, maltose, trehalose, raffinose, glucosamine, galactosamine, lactosamine, or derivatives of disaccharides with at least two pyranose saccharide units, trisaccharides, tetrasaccharides, or mixtures thereof, and wherein the composition is a liquid before administration into the human or animal body and increases in viscosity by more than 1,000 centipoise (cP) after administration, for use as a medicament.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 20, 2021
    Assignee: TECHNICAL UNIVERSITY OF DENMARK
    Inventors: Thomas Lars Andresen, Linda Maria Bruun, Trine Bjørnbo Larsen, Rasmus Irming Jølck, Anders Elias Hansen
  • Patent number: 11065349
    Abstract: This invention provides a class of dual mode imaging tracer capable of acting both as a fluorescent imaging tracer and a positron emission tomography imaging tracer. Tracers in accordance with this invention generally have a fluorescent core with a boron-fluoride element embedded therein. Exemplary embodiments of the tracer include 18F-labeled BODIPY compounds and derivative thereof. Also provided are tracer kits containing a sterile formulation of a BODIPY dye either in a radio-labeled or pre-labeled state, and methods for imaging heart perfusion using the 18F-labeled dual mode tracers.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 20, 2021
    Inventors: Peter S. Conti, Zibo Li, Shuanglong Liu, Dan Li
  • Patent number: 11059825
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: July 13, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Patent number: 11059836
    Abstract: Provided are imaging agents comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and methods of their use.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: July 13, 2021
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Samuel Coe, Peter David Johnson, Michael Edward Prime, Christopher John Brown, Sébastien René Gabriel Galan, Paul Richard Giles, Jonathan Bard, Elise Luciennen Paulette Gadouleau, Thomas Martin Krülle, Daniel Clark-Frew, John Wityak, Alex Kiselyov, Sarah Hayes
  • Patent number: 11052164
    Abstract: The present disclosure relates to polymeric materials that may be labeled with a radioisotope, to processes for producing the labeled polymeric material, and to methods of using the materials in analytical and therapeutic applications. Specifically, the disclosure relates to injectable and implantable microparticles, such as microspheres, which are associated with radioisotopes such that the microparticles are both therapeutic and detectable. The radioisotope-containing microparticles are useful for embolization and other therapeutic medical applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: July 6, 2021
    Assignee: Biosphere Medical, Inc.
    Inventors: Philippe Reb, Celine Chaix
  • Patent number: 11052157
    Abstract: Enhanced loading of small molecule compounds into intact, bacterially derived vesicles provides operational and therapeutic advantages.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: July 6, 2021
    Assignee: ENGENEIC MOLECULAR DELIVERY PTY LTD.
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 11045564
    Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer. Thus, the present invention concerns compounds that are represented by the general Formulae (Ia) or (Ib).
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 29, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Matthias Eder, Klaus Kopka, Martin Schäfer, Ulrike Bauder-Wüst, Michael Eisenhut, Walter Mier, Martina Benesova
  • Patent number: 11041928
    Abstract: A method tor the preparation of a highly polarized nuclear spins containing sample of an organic or inorganic material, containing H or OH groups or adsorbed water molecules. Such highly polarized nuclear spins containing samples can be subjected to nuclear magnetic resonance (NMR) measurement and/or can be thawed and immediately administered to an individual undergoing a magnetic resonance imaging (MRI) scan. The method is based on generating unstable radicals on the surface of the sample in the presence of ionized environment followed by cooling the sample to cryogenic temperatures. A device for carrying out a particular step of said method is also discloses.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: June 22, 2021
    Assignees: Technion Research & Development Foundation Limited, Yeda Research and Development Co. Ltd.
    Inventors: Aharon Blank, Itai Katz, Akiva Feintuch
  • Patent number: 11017910
    Abstract: A method for producing an iodine radioisotopes fraction, comprising the steps of dissolving enriched uranium targets forming a slurry, filtering said slurry, absorbing salts of iodine radioisotopes on an aluminium resin doped with silver and recovering said iodine radioisotopes fraction, is disclosed. The recovery of the iodine radioisotopes fraction, in particular of I-131, comprises washing the aluminium resin doped in silver using a solution of NaOH and eluting of iodine radioisotopes by a solution of thiourea, and collecting an eluate containing said iodine radioisotopes in a thiourea solution.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: May 25, 2021
    Assignee: INSTITUT NATIONAL DES RADIOÉLÉMENTS
    Inventors: Dominique Moyaux, Valery Host, Caroline Decamp
  • Patent number: 10994014
    Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: May 4, 2021
    Assignee: EnGeneIC Molecular Delivery Pty Ltd
    Inventors: Himanshu Brahmbhatt, Jennifer MacDiarmid
  • Patent number: 10994058
    Abstract: A flexible or elastic brachytherapy strand that includes an imaging marker and/or a therapeutic, diagnostic or prophylactic agent such as a drug in a biocompatible carrier that can be delivered to a subject upon implantation into the subject through the bore of a brachytherapy implantation needle has been developed. Strands can be formed as chains or continuous arrays of seeds up to 50 centimeters or more, with or without spacer material, flaccid, rigid, or flexible.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: May 4, 2021
    Assignee: MICROSPHERIX LLC
    Inventor: Edward J. Kaplan
  • Patent number: 10981912
    Abstract: A macrocycle compound of general formula (X) in which Y1 represents a C(O)OH group or a group of formula (II)
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: April 20, 2021
    Assignees: GUERBET, UNIVERSITE DE BRETAGNE OCCIDENTALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Mariane Le Fur, Raphaël Tripier, Olivier Rousseaux, Maryline Beyler